BioNTech’s Strong Oncology Pipeline and COVID-19 Vaccine Performance Earns Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
FiercePharma1d
BioNTech reports surprising COVID vaccine sales in Q3 but tempers expectations for annual sales
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...
BioNTech SE: Strong Financial Performance and Promising Future Justify Buy Rating
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
2,051 Shares in BioNTech SE (NASDAQ:BNTX) Purchased by Mount Yale Investment Advisors LLC
Mount Yale Investment Advisors LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the ...
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...
BioNTech SE Reports Strong Revenue Growth Amid Rising R&D Costs
BioNTech SE (BNTX) has released an update. BioNTech SE’s quarterly report for the period ending September 30, 2024, reveals a ...
Pfizer raises guidance as COVID franchise drives Q3 beat
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...